Free Trial

Disc Medicine, Inc. $IRON Shares Sold by Pictet Asset Management Holding SA

Disc Medicine logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Pictet Asset Management cut its Disc Medicine stake by 67.2% in the third quarter, selling 259,142 shares and ending the period with 126,233 shares valued at about $8.3 million.
  • Disc Medicine insiders sold 150,277 shares worth about $11.9 million over the past 90 days. Director Kevin Bitterman’s sale was made under a pre-arranged Rule 10b5-1 plan.
  • Analysts give the stock a consensus “Moderate Buy” rating and a $124.18 average target price. The company’s quarterly loss of $1.53 per share was narrower than the $1.63 loss analysts expected.
  • Interested in Disc Medicine? Here are five stocks we like better.

Pictet Asset Management Holding SA decreased its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 67.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 126,233 shares of the company's stock after selling 259,142 shares during the period. Pictet Asset Management Holding SA owned approximately 0.33% of Disc Medicine worth $8,263,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Disc Medicine in the 2nd quarter valued at approximately $180,502,000. Wellington Management Group LLP raised its position in Disc Medicine by 0.3% in the second quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company's stock worth $127,362,000 after acquiring an additional 5,975 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in Disc Medicine by 191.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company's stock valued at $73,280,000 after acquiring an additional 735,300 shares during the period. Opaleye Management Inc. lifted its holdings in Disc Medicine by 103.1% in the second quarter. Opaleye Management Inc. now owns 855,000 shares of the company's stock valued at $62,535,000 after acquiring an additional 434,000 shares during the period. Finally, Jennison Associates LLC boosted its position in shares of Disc Medicine by 14.7% during the 1st quarter. Jennison Associates LLC now owns 610,382 shares of the company's stock worth $39,028,000 after purchasing an additional 78,303 shares in the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Disc Medicine

In other news, Director Kevin Bitterman sold 25,519 shares of Disc Medicine stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $80.23, for a total transaction of $2,047,389.37. Following the completion of the sale, the director directly owned 12,991 shares in the company, valued at $1,042,267.93. The trade was a 66.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider William Savage sold 16,035 shares of Disc Medicine stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $85.09, for a total transaction of $1,364,418.15. Following the completion of the sale, the insider directly owned 63,445 shares of the company's stock, valued at $5,398,535.05. The trade was a 20.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 150,277 shares of company stock valued at $11,877,059. 3.76% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on IRON shares. Wall Street Zen upgraded shares of Disc Medicine from a "sell" rating to a "hold" rating in a research report on Saturday, November 7th. HC Wainwright boosted their price target on Disc Medicine from $120.00 to $127.00 and gave the stock a "buy" rating in a research note on Friday, November 6th. Jefferies Financial Group restated a "buy" rating and issued a $149.00 price target on shares of Disc Medicine in a report on Wednesday, October 21st. Morgan Stanley raised their price objective on Disc Medicine from $90.00 to $92.00 and gave the company an "overweight" rating in a research note on Tuesday, October 20th. Finally, Truist Financial lifted their price objective on Disc Medicine from $83.00 to $115.00 and gave the stock a "buy" rating in a report on Monday, October 19th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $124.18.

Read Our Latest Analysis on IRON

Disc Medicine Price Performance

IRON stock opened at $80.00 on Monday. The company's 50 day simple moving average is $71.60 and its 200-day simple moving average is $71.07. The firm has a market capitalization of $3.64 billion, a PE ratio of -12.62 and a beta of 0.96. Disc Medicine, Inc. has a 12 month low of $40.00 and a 12 month high of $99.50. The company has a debt-to-equity ratio of 0.10, a current ratio of 20.30 and a quick ratio of 20.30.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.53) earnings per share for the quarter, topping analysts' consensus estimates of ($1.63) by $0.10. Equities analysts expect that Disc Medicine, Inc. will post -6.20 earnings per share for the current fiscal year.

Disc Medicine Profile

(Free Report)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function. The company's development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.

Further Reading

Want to see what other hedge funds are holding IRON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Disc Medicine, Inc. (NASDAQ:IRON - Free Report).

Institutional Ownership by Quarter for Disc Medicine (NASDAQ:IRON)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Disc Medicine Right Now?

Before you consider Disc Medicine, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.

While Disc Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines